Endologix to Participate in Two Investor Conferences in September 2016

IRVINE, Calif., Sept. 06, 2016 -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chief Executive Officer, is scheduled to participate at two investor conferences in September 2016. The first conference is the Morgan Stanley Global Healthcare Conference 2016 in New York, NY.

The second conference is the 7th Annual Credit Suisse Small & Mid Cap Conference in New York, NY. This conference will allow institutional investors to meet with the Company but does not include a formal presentation.

An audio webcast of the Company’s presentation at the Morgan Stanley Global Healthcare Conference 2016 will be available by visiting the investor relations section of Endologix’s website at www.endologix.com. A replay of the presentation will be available for 30 days.

About Endologix, Inc.
Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.

COMPANY CONTACT:
Endologix, Inc.
John McDermott, CEO
Vaseem Mahboob, CFO
(949) 595-7200
www.endologix.com 

INVESTOR CONTACTS:
The Ruth Group
Nick Laudico (646) 536-7030
Zack Kubow (646) 536-7020